Mylan are one of the world’s leading generics and specialty pharmaceutical companies, selling products in approximately 165 countries and territories. Mylan entered the Australian market in 2007, following its acquisition of Alphapharm, a company supplying generic medicines in Australia since 1982. Together, they have built on this legacy in providing patients greater access to affordable medicine in Australia and around the world.In Australia, Mylan is the leading supplier of medicines by volume to the Pharmaceutical Benefits Scheme (PBS)*. One in six PBS-subsidised medicines dispensed is a Mylan product*. This contributes to the sustainability of the PBS by providing timely access for patients to quality, safe, efficacious and affordable medicines.Since pioneering generic substitution of medicines in Australia, Mylan has transformed into one of Australia’s leading healthcare companies. Global acquisitions of Abbott’s non-U.S. developed markets speciality and branded generics business and Meda have enabled Mylan to evolve it's patient and pharmacy offering. Along with it's generics business, Mylan offers a range of innovative brands and over the counter medicines, to offer Australian patients a range of choice for their medical needs.